Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 50 条

[21] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Rifkin, Robert
Boyd, Kevin
Grosicki, Sebastian
Kim, Kihyun
Di Raimondo, Francesco
Dimopoulos, Meletios
Weisel, Katja
Arnulf, Bertrand
Hajek, Roman
Hungria, Vania
Spencer, Andrew
Davis, Randy
Riccio, Antonio
Kim, Chanbin
Wilkes, Jodie
Rutledge, Ruth
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Mateos Manteca, Maria Victoria
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 172 - 173
[22] Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
Cardellino, Anna
Correll, Julia R.
Martin, Mona
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
FRONTIERS IN ONCOLOGY, 2023, 13
[23] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Nooka, Ajay
Stockerl-Goldstein, Keith
Abonour, Rafat
Ramaekers, Ryan
Khot, Amit
Forbes, Adam
Lee, Cindy
Augustson, Bradley
Spencer, Andrew
Mateos, Maria-Victoria
Chopra, Bikramjit
Rogers, Rachel
Smith, Deborah A.
Davidge, Jacqueline
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Yeakey, Anne
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Quach, Hang
BLOOD, 2020, 136
[24] Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
Nooka, Ajay K.
Cohen, Adam
Lee, Hans C.
Badros, Ashraf Z.
Suvannasankha, Attaya
Callander, Natalie
Abdallah, Al-Ola
Trudel, Suzanne
Chari, Ajai
Libby, Edward
Chaudhry, Maria
Hultcrantz, Malin
Kortuem, Martin
Richardson, Paul G.
Popat, Rakesh
Sborov, Douglas W.
Hakim, Shawn
Lewis, Eric
Bhushan, Bharat
Gorsh, Boris
Gupta, Ira
Opalinska, Joanna
Lonial, Sagar
BLOOD, 2022, 140 : 7301 - 7303
[25] Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
Ramasamy, Karthik
Nooka, Ajay
Cohen, Adam
Lee, Hans
Badros, Ashraf
Suvannasankha, Attaya
Callander, Natalie
Abdallah, Al-Ola
Trudel, Suzanne
Chari, Ajai
Libby, Edward
Chaudhry, Maria
Hultcrantz, Malin
Kortuem, K. Martin
Richardson, Paul
Popat, Rakesh
Sborov, Douglas
Hakim, Shawn
Lewis, Eric
Bhushan, Bharat
Gorsh, Boris
Gupta, Ira
Opalinska, Joanna
Lonial, Sagar
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 68 - 69
[26] BELANTAMAB MAFODOTIN IN A PATIENT WITH REFRACTORY MULTIPLE MYELOMA
Luz Gema, Roman
Borja, Puertas
Alberto, Hernandez
Sandra, Gomez
Felipe, Pena
Danylo, Palomino
Bea, Rey
Marta, Fonseca
Raul, Azibeiro
Elena, Alejo
David, Alonso
Jose Maria, Navarro
Veronica, Gonzalez
Noemi, Puig
Maria Victoria, Mateos
HAEMATOLOGICA, 2021, 106 (10) : 334 - 334
[27] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[28] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Delforge, Michel
Kotowsky, Nirali
Bitetti, Jacopo
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Happ, Lindsey Powers
Rohman, Mujib
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
[29] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines, Andrea C.
Ershler, Rachel
Kanapuru, Bindu
Xu, Qing
Shen, Guoxiang
Li, Liang
Ma, Lian
Okusanya, Olanrewaju O.
Simpson, Natalie E.
Nguyen, Wanda
Theoret, Marc R.
Pazdur, Richard
Gormley, Nicole J.
CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
[30] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G. Richardson
Hans C. Lee
Al-Ola Abdallah
Adam D. Cohen
Prashant Kapoor
Peter M. Voorhees
Axel Hoos
Karrie Wang
January Baron
Trisha Piontek
Julie Byrne
Scott Richmond
Roxanne C. Jewell
Joanna Opalinska
Ira Gupta
Sagar Lonial
Blood Cancer Journal, 10

← 1 2 3 4 5 →